{
    "xml": "<topic id=\"PHP5701\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/fingolimod\" basename=\"fingolimod\" title=\"FINGOLIMOD\">\n<title>FINGOLIMOD</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1202\" namespace=\"/interactions/list-of-drug-interactions/fingolimod\">Fingolimod</xref>\n</p>\n<data name=\"vtmid\">18750111000001103</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_732340950\" title=\"Immunomodulating drugs\">Immunomodulating drugs</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP45711\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/fingolimod\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Fingolimod is an immunomodulating drug.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45678\" outputclass=\"indicationsAndDose\" rev=\"1.30\" parent=\"/drugs/fingolimod\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of highly active relapsing-remitting multiple sclerosis in patients who have high disease activity despite treatment with at least one disease modifying therapy or in those with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>500&#8239;micrograms once daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45726\" outputclass=\"importantSafetyInformation\" rev=\"1.10\" parent=\"/drugs/fingolimod\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">MHRA/CHM advice: Fingolimod&#8212;not recommended for patients at known risk of cardiovascular events. Advice for extended monitoring for those with significant bradycardia or heart block after the first dose and following treatment interruption (January 2013) </p>\n<p>Fingolimod is known to cause transient bradycardias and heart block after the first dose. Fingolimod is not recommended in the following patient groups who are at high risk of cardiovascular events unless the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought before initiation:</p>\n<p>\n<b>Patients with the following medical conditions</b>:</p>\n<ul>\n<li>2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block</li>\n<li>significant QT prolongation (QT-interval greater than 470&#8239;milliseconds in women, or greater than 450&#8239;milliseconds in men)</li>\n<li>history of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnoea.</li>\n</ul>\n<p>\n<b>Patients receiving the following antiarrhythmic or heart-rate lowering drugs</b>:</p>\n<ul>\n<li>class Ia or class III antiarrhythmics</li>\n<li>beta blockers </li>\n<li>heart rate-lowering calcium channel blockers </li>\n<li>other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic drugs or pilocarpine).</li>\n</ul>\n<p>\n<b>All</b> patients receiving fingolimod should be monitored at treatment initiation, (first dose monitoring), and after treatment interruption (see note below); monitoring should include:</p>\n<p>\n<b>Pre-treatment</b>\n</p>\n<ul>\n<li>a 12-lead ECG and blood pressure measurement before starting</li>\n</ul>\n<p>\n<b>During the first 6 hours of treatment</b>\n</p>\n<ul>\n<li>continuous ECG monitoring for 6 hours</li>\n<li>blood pressure and heart rate measurement every hour</li>\n</ul>\n<p>\n<b>After 6 hours of treatment</b>\n</p>\n<ul>\n<li>a further 12-lead ECG and blood pressure measurement</li>\n</ul>\n<p>If heart rate at the end of the 6 hour period is at its lowest since fingolimod was first administered, monitoring should be extended by at least 2 hours and until heart rate increases.</p>\n<p>Extended monitoring, (at least overnight), should be performed in patients with evidence of clinically important cardiac effects during first dose monitoring. Monitoring in patients requiring pharmacological intervention for bradyarrhythmia-related symptoms during first dose monitoring should be extended at least overnight, and first dose monitoring should be repeated after the second dose.</p>\n<p>\n<b>Note</b>\n</p>\n<p>First dose monitoring as above <b>should be repeated</b> in all patients whose treatment is interrupted for:</p>\n<ul>\n<li>1 day or more during the first 2 weeks of treatment</li>\n<li>more than 7 days during weeks 3 and 4 of treatment</li>\n<li>more than 2 weeks after one month of treatment</li>\n</ul>\n<p>If the treatment interruption is of shorter duration than the above, repeated monitoring is not required and treatment should be continued with the next dose as planned.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45739\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/fingolimod\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active infection</ph>; <ph outputclass=\"contraindication\">active malignancies (except cutaneous basal cell carcinoma)</ph>; <ph outputclass=\"contraindication\">immunosuppression</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45766\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/fingolimod\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Check varicella zoster virus status&#8212;consult product literature for further information</ph>; <ph outputclass=\"caution\">chronic obstructive pulmonary disease</ph>; <ph outputclass=\"caution\">pulmonary fibrosis</ph>; <ph outputclass=\"caution\">risk of macular oedema</ph>; <ph outputclass=\"caution\">severe respiratory disease</ph>; <ph outputclass=\"caution\">susceptibility to QT-interval prolongation (including electrolyte disturbances)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45673\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/fingolimod\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (fingolimod).</p>\n<p>Caution with concomitant use of drugs that prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45636\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/fingolimod\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">AV block</ph>; <ph outputclass=\"sideEffect\">back pain</ph>; <ph outputclass=\"sideEffect\">blurred vision</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>; <ph outputclass=\"sideEffect\">bronchitis</ph>; <ph outputclass=\"sideEffect\">cough</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dyspnoea</ph>; <ph outputclass=\"sideEffect\">eczema</ph>; <ph outputclass=\"sideEffect\">eye pain</ph>; <ph outputclass=\"sideEffect\">gastroenteritis</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">herpes</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">influenza</ph>; <ph outputclass=\"sideEffect\">leucopenia</ph>; <ph outputclass=\"sideEffect\">lymphopenia</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">migraine</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">sinusitis</ph>; <ph outputclass=\"sideEffect\">tinea</ph>; <ph outputclass=\"sideEffect\">weight loss</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Macular oedema</ph>; <ph outputclass=\"sideEffect\">neutropenia</ph>; <ph outputclass=\"sideEffect\">pneumonia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Haemophagocytic syndrome</ph>; <ph outputclass=\"sideEffect\">lymphoma</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45753\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/fingolimod\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment.</p>\n<p>Ensure effective contraception during and for at least 2 months after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45668\" outputclass=\"pregnancy\" parent=\"/drugs/fingolimod\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (toxicity in <i>animal</i> studies).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45777\" outputclass=\"breastFeeding\" parent=\"/drugs/fingolimod\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45688\" outputclass=\"hepaticImpairment\" parent=\"/drugs/fingolimod\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution in mild to moderate impairment.</p>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45589\" outputclass=\"monitoringRequirements\" parent=\"/drugs/fingolimod\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Eye examination recommended 3&#8211;4 months after initiation of treatment (and before initiation of treatment in patients with diabetes or history of uveitis).</p>\n<p>Monitor hepatic transaminases before treatment, then every 3 months for 1 year, then periodically thereafter.</p>\n<p>Monitor full blood count before treatment, at 3 months, then at least yearly thereafter and if signs of infection&#8212; interrupt treatment if lymphocyte count reduced&#8212;consult product literature.</p>\n<p>Monitor for signs and symptoms of haemophagocytic syndrome (including pyrexia, asthenia, hepato-splenomegaly and adenopathy&#8212;may be associated with hepatic failure and respiratory distress; also progressive cytopenia, elevated serum-ferritin concentrations, hypertriglyceridaemia, hypofibrinogenaemia, coagulopathy, hepatic cytolysis, hyponatraemia)&#8212;initiate treatment immediately.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP45540\" outputclass=\"nationalFunding\" rev=\"1.17\" parent=\"/drugs/fingolimod\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA254</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis (April 2012)</p>\r\n<p>Fingolimod is recommended as an option for the treatment of highly active relapsing-remitting multiple sclerosis in adults, only if:</p>\r\n<ul>\r\n<li>they have an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta, <b>and</b>\r\n</li>\r\n<li>the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme</li>\r\n</ul>\r\n<p>Patients currently receiving fingolimod whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA254\">www.nice.org.uk/TA254</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (August 2012) that fingolimod (<i>Gilenya</i>\r\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland as single disease modifying therapy in highly active relapsing-remitting multiple sclerosis despite treatment with interferon beta, with an unchanged or increased relapse rate or ongoing severe relapses, as compared to the previous year.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5701-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/fingolimod\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75194\" title=\"Capsule\" namespace=\"/drugs/fingolimod/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1202\" namespace=\"/interactions/list-of-drug-interactions/fingolimod\" title=\"Fingolimod\" count=\"1\" rel=\"link\">Fingolimod</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75194\" namespace=\"/drugs/fingolimod/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP5701",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/fingolimod",
    "basename": "fingolimod",
    "title": "FINGOLIMOD",
    "interactants": [
        {
            "id": "bnf_int_1202",
            "label": "Fingolimod"
        }
    ],
    "vtmid": "18750111000001103",
    "drugClassification": [
        "Immunomodulating drugs"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Fingolimod is an immunomodulating drug.",
                "html": "<p>Fingolimod is an immunomodulating drug.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of highly active relapsing-remitting multiple sclerosis in patients who have high disease activity despite treatment with at least one disease modifying therapy or in those with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)",
                        "html": "Treatment of highly active relapsing-remitting multiple sclerosis in patients who have high disease activity despite treatment with at least one disease modifying therapy or in those with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "500 micrograms once daily.",
                        "html": "<p>500&#8239;micrograms once daily.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice: Fingolimod&#8212;not recommended for patients at known risk of cardiovascular events. Advice for extended monitoring for those with significant bradycardia or heart block after the first dose and following treatment interruption (January 2013)",
                "textContent": "Fingolimod is known to cause transient bradycardias and heart block after the first dose. Fingolimod is not recommended in the following patient groups who are at high risk of cardiovascular events unless the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought before initiation:\n\nPatients with the following medical conditions:\n\n2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block significant QT prolongation (QT-interval greater than 470 milliseconds in women, or greater than 450 milliseconds in men) history of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnoea.\n\nPatients receiving the following antiarrhythmic or heart-rate lowering drugs:\n\nclass Ia or class III antiarrhythmics beta blockers heart rate-lowering calcium channel blockers other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic drugs or pilocarpine).\n\nAll patients receiving fingolimod should be monitored at treatment initiation, (first dose monitoring), and after treatment interruption (see note below); monitoring should include:\n\nPre-treatment\n\na 12-lead ECG and blood pressure measurement before starting\n\nDuring the first 6 hours of treatment\n\ncontinuous ECG monitoring for 6 hours blood pressure and heart rate measurement every hour\n\nAfter 6 hours of treatment\n\na further 12-lead ECG and blood pressure measurement\n\nIf heart rate at the end of the 6 hour period is at its lowest since fingolimod was first administered, monitoring should be extended by at least 2 hours and until heart rate increases.\n\nExtended monitoring, (at least overnight), should be performed in patients with evidence of clinically important cardiac effects during first dose monitoring. Monitoring in patients requiring pharmacological intervention for bradyarrhythmia-related symptoms during first dose monitoring should be extended at least overnight, and first dose monitoring should be repeated after the second dose.\n\nNote\n\nFirst dose monitoring as above should be repeated in all patients whose treatment is interrupted for:\n\n1 day or more during the first 2 weeks of treatment more than 7 days during weeks 3 and 4 of treatment more than 2 weeks after one month of treatment\n\nIf the treatment interruption is of shorter duration than the above, repeated monitoring is not required and treatment should be continued with the next dose as planned.",
                "html": "<p>Fingolimod is known to cause transient bradycardias and heart block after the first dose. Fingolimod is not recommended in the following patient groups who are at high risk of cardiovascular events unless the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought before initiation:</p><p>\n<b>Patients with the following medical conditions</b>:</p><ul>\n<li>2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block</li>\n<li>significant QT prolongation (QT-interval greater than 470&#8239;milliseconds in women, or greater than 450&#8239;milliseconds in men)</li>\n<li>history of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnoea.</li>\n</ul><p>\n<b>Patients receiving the following antiarrhythmic or heart-rate lowering drugs</b>:</p><ul>\n<li>class Ia or class III antiarrhythmics</li>\n<li>beta blockers </li>\n<li>heart rate-lowering calcium channel blockers </li>\n<li>other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic drugs or pilocarpine).</li>\n</ul><p>\n<b>All</b> patients receiving fingolimod should be monitored at treatment initiation, (first dose monitoring), and after treatment interruption (see note below); monitoring should include:</p><p>\n<b>Pre-treatment</b>\n</p><ul>\n<li>a 12-lead ECG and blood pressure measurement before starting</li>\n</ul><p>\n<b>During the first 6 hours of treatment</b>\n</p><ul>\n<li>continuous ECG monitoring for 6 hours</li>\n<li>blood pressure and heart rate measurement every hour</li>\n</ul><p>\n<b>After 6 hours of treatment</b>\n</p><ul>\n<li>a further 12-lead ECG and blood pressure measurement</li>\n</ul><p>If heart rate at the end of the 6 hour period is at its lowest since fingolimod was first administered, monitoring should be extended by at least 2 hours and until heart rate increases.</p><p>Extended monitoring, (at least overnight), should be performed in patients with evidence of clinically important cardiac effects during first dose monitoring. Monitoring in patients requiring pharmacological intervention for bradyarrhythmia-related symptoms during first dose monitoring should be extended at least overnight, and first dose monitoring should be repeated after the second dose.</p><p>\n<b>Note</b>\n</p><p>First dose monitoring as above <b>should be repeated</b> in all patients whose treatment is interrupted for:</p><ul>\n<li>1 day or more during the first 2 weeks of treatment</li>\n<li>more than 7 days during weeks 3 and 4 of treatment</li>\n<li>more than 2 weeks after one month of treatment</li>\n</ul><p>If the treatment interruption is of shorter duration than the above, repeated monitoring is not required and treatment should be continued with the next dose as planned.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active infection",
                "html": "Active infection"
            },
            {
                "type": "contraindications",
                "textContent": "active malignancies (except cutaneous basal cell carcinoma)",
                "html": "active malignancies (except cutaneous basal cell carcinoma)"
            },
            {
                "type": "contraindications",
                "textContent": "immunosuppression",
                "html": "immunosuppression"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Check varicella zoster virus status&#8212;consult product literature for further information",
                "html": "Check varicella zoster virus status&#8212;consult product literature for further information"
            },
            {
                "type": "cautions",
                "textContent": "chronic obstructive pulmonary disease",
                "html": "chronic obstructive pulmonary disease"
            },
            {
                "type": "cautions",
                "textContent": "pulmonary fibrosis",
                "html": "pulmonary fibrosis"
            },
            {
                "type": "cautions",
                "textContent": "risk of macular oedema",
                "html": "risk of macular oedema"
            },
            {
                "type": "cautions",
                "textContent": "severe respiratory disease",
                "html": "severe respiratory disease"
            },
            {
                "type": "cautions",
                "textContent": "susceptibility to QT-interval prolongation (including electrolyte disturbances)",
                "html": "susceptibility to QT-interval prolongation (including electrolyte disturbances)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (fingolimod).\n\nCaution with concomitant use of drugs that prolong QT interval.",
                "html": "<p>Appendix 1 (fingolimod).</p><p>Caution with concomitant use of drugs that prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "AV block",
                        "html": "AV block",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "back pain",
                        "html": "back pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "blurred vision",
                        "html": "blurred vision",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "bronchitis",
                        "html": "bronchitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cough",
                        "html": "cough",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspnoea",
                        "html": "dyspnoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "eczema",
                        "html": "eczema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "eye pain",
                        "html": "eye pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "gastroenteritis",
                        "html": "gastroenteritis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "herpes",
                        "html": "herpes",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "influenza",
                        "html": "influenza",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "leucopenia",
                        "html": "leucopenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "lymphopenia",
                        "html": "lymphopenia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "migraine",
                        "html": "migraine",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "sinusitis",
                        "html": "sinusitis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tinea",
                        "html": "tinea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "weight loss",
                        "html": "weight loss",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Macular oedema",
                        "html": "Macular oedema",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "neutropenia",
                        "html": "neutropenia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "pneumonia",
                        "html": "pneumonia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Haemophagocytic syndrome",
                        "html": "Haemophagocytic syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "lymphoma",
                        "html": "lymphoma",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment.\n\nEnsure effective contraception during and for at least 2 months after treatment.",
                "html": "<p>Exclude pregnancy before treatment.</p><p>Ensure effective contraception during and for at least 2 months after treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (toxicity in animal studies).",
                "html": "<p>Avoid (toxicity in <i>animal</i> studies).</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid.",
                "html": "<p>Avoid.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution in mild to moderate impairment.\n\nAvoid in severe impairment.",
                "html": "<p>Use with caution in mild to moderate impairment.</p><p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Eye examination recommended 3&#8211;4 months after initiation of treatment (and before initiation of treatment in patients with diabetes or history of uveitis).\n\nMonitor hepatic transaminases before treatment, then every 3 months for 1 year, then periodically thereafter.\n\nMonitor full blood count before treatment, at 3 months, then at least yearly thereafter and if signs of infection&#8212; interrupt treatment if lymphocyte count reduced&#8212;consult product literature.\n\nMonitor for signs and symptoms of haemophagocytic syndrome (including pyrexia, asthenia, hepato-splenomegaly and adenopathy&#8212;may be associated with hepatic failure and respiratory distress; also progressive cytopenia, elevated serum-ferritin concentrations, hypertriglyceridaemia, hypofibrinogenaemia, coagulopathy, hepatic cytolysis, hyponatraemia)&#8212;initiate treatment immediately.",
                "html": "<p>Eye examination recommended 3&#8211;4 months after initiation of treatment (and before initiation of treatment in patients with diabetes or history of uveitis).</p><p>Monitor hepatic transaminases before treatment, then every 3 months for 1 year, then periodically thereafter.</p><p>Monitor full blood count before treatment, at 3 months, then at least yearly thereafter and if signs of infection&#8212; interrupt treatment if lymphocyte count reduced&#8212;consult product literature.</p><p>Monitor for signs and symptoms of haemophagocytic syndrome (including pyrexia, asthenia, hepato-splenomegaly and adenopathy&#8212;may be associated with hepatic failure and respiratory distress; also progressive cytopenia, elevated serum-ferritin concentrations, hypertriglyceridaemia, hypofibrinogenaemia, coagulopathy, hepatic cytolysis, hyponatraemia)&#8212;initiate treatment immediately.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA254",
                        "label": "www.nice.org.uk/TA254"
                    }
                ],
                "fundingIdentifier": "NICE TA254",
                "textContent": "Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis (April 2012) Fingolimod is recommended as an option for the treatment of highly active relapsing-remitting multiple sclerosis in adults, only if: they have an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta, and the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme Patients currently receiving fingolimod whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA254",
                "html": "<p outputclass=\"title\">Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis (April 2012)</p> <p>Fingolimod is recommended as an option for the treatment of highly active relapsing-remitting multiple sclerosis in adults, only if:</p> <ul> <li>they have an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta, <b>and</b> </li> <li>the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme</li> </ul> <p>Patients currently receiving fingolimod whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA254\">www.nice.org.uk/TA254</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75194",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1202",
                "label": "Fingolimod",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75194",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}